Developer docs
API playgroundTry for free, no card

Search company profiles

Toregem BioPharma

Full company profile

uuid0000tx2

Namestring
Toregem BioPharma
Legal namestring
トレジェムバイオファーマ株式会社
Websiteurl
toregem.co.jp
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Toregem BioPharma Co., Ltd. is a privately held, Kyoto University spin-off biopharmaceutical company founded in May 2020 to develop the world's first therapeutic that regenerates natural human teeth. The company's lead and only clinical asset is TRG035, a humanized monoclonal antibody that neutralizes USAG-1 (Uterine Sensitization-Associated Gene-1), a protein that normally inhibits tooth bud development; by blocking USAG-1, TRG035 is intended to reactivate dormant tooth buds and induce the growth of new natural teeth. The technology originated from over two decades of basic research by co-founder and CTO Dr. Katsu Takahashi at Kyoto University Graduate School of Medicine, with proof-of-concept demonstrated in animal models (mice, ferrets, dogs) and published in Science Advances in 2021.

The company's initial therapeutic focus is severe congenital partial anodontia (先天性無歯症), a rare genetic condition where patients lack permanent tooth buds. TRG035 received Japan MHLW Orphan Drug designation in September 2025, completed domestic Phase I clinical trials without serious adverse events, and is now preparing for Phase II trials in Japan while concurrently advancing US clinical development following a successful US FDA Pre-IND meeting in November 2025. The stated longer-term ambition is to expand the same mechanism into acquired tooth loss (cavities, periodontal disease, trauma) and elderly oral frailty, addressing a potential Japanese patient population of approximately 3 million.

Toregem generates no commercial revenue; the company is funded entirely by equity financing and government/non-dilutive grants. Cumulative funding including subsidies reached approximately JPY 4.6 billion (USD 29 million) as of May 2026, with a Pre-Series C round of JPY 850 million (USD 5.3 million) led by JIC Venture Growth Investments. The company employs 13 people as of April 2026 and operates from Kyoto, Japan. The GTM motion is sales-led to medical institutions via investigator-initiated clinical trials, with future commercial distribution planned through standard pharmaceutical channels upon regulatory approval.

Short descriptiontext

Toregem BioPharma is a Kyoto University spin-off developing TRG035, a humanized anti-USAG-1 antibody designed to regenerate natural teeth in patients with congenital edentulism. The clinical-stage biotech is preparing Phase II trials in Japan and US clinical entry, targeting rare genetic tooth agenesis first.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKyoto, Japan
HQ citystring
Kyoto
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tooth regeneration therapeutics, anti-USAG-1 antibody, regenerative biopharmaceuticals, congenital edentulism treatment, clinical stage biotechnology
Industry2 codes
PRIMARYHLABACAI
Periodontal Regeneration (GTR/EMD/Biologics)
Healthcare & Life Sciences/Dental Care Services/Periodontics (Gum & Implant Services)
SECONDARYHLABAAAA
Preventive & Routine General Dentistry (Exams/Cleanings/Sealants/Fluoride)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Offices of Dentists62121
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Regenerative Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Tooth Regeneration Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing a novel tooth regeneration treatment (TRG035). Revenue will be generated through product sales upon successful clinical development and regulatory approval.

toregem.co.jp
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Toregem BioPharma is developing TRG035, a humanized anti-USAG-1 neutralizing monoclonal antibody that suppresses the USAG-1 protein, which normally inhibits tooth bud growth, thereby enabling patients' own dormant tooth buds to develop into natural teeth. The lead indication is congenital edentulism (congenital tooth agenesis), with future expansion planned to acquired tooth loss and oral frailty in the elderly; the product is currently advancing through Phase II clinical trials in Japan and pre-IND regulatory engagement with the US FDA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I clinical trials at Kyoto University Hospital completed without serious adverse events
+2 more records
Product overview1 text field

Toregem BioPharma is developing a single core product: TRG035, a humanized anti-USAG-1 antibody drug for tooth regeneration. The company is pursuing clinical development of this first-in-class regenerative antibody therapeutic, initially targeting congenital edentulism (congenital tooth agenesis), with plans to eventually expand to acquired tooth loss and oral frailty in the elderly. The product works by suppressing the USAG-1 protein that inhibits tooth bud growth, allowing new natural teeth to develop.

Product and service1 record
1TRG035 (Anti-USAG-1 Antibody)
CategoryRegenerative biopharmaceutical - therapeutic antibody
Description

A humanized anti-USAG-1 neutralizing monoclonal antibody drug designed to suppress the USAG-1 protein that inhibits tooth bud growth, enabling patients' own dormant tooth buds to develop into natural teeth. Intended for congenital edentulism (initial indication) and planned expansion to acquired tooth loss; administered as a single injection. Currently in Phase II clinical development in Japan with parallel US FDA Pre-IND engagement.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1京都大学 (Kyoto University)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-01
Description

Technology origin - company founded based on research from Kyoto University Graduate School of Medicine, Department of Oral and Maxillofacial Surgery led by Dr. Katsu Takahashi.

toregem.co.jp
2公益ражение田附興風会医学研究所北野病院 (Kitano Hospital, Tazuke Kofukai Medical Research Institute)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-01
Description

Clinical trial partner conducting investigator-initiated clinical trials for tooth regeneration treatment. Dr. Takahashi serves as Chief of Oral and Maxillofacial Surgery.

toregem.co.jp
3東北大学東北リカール・メガバンク機構 (Tohoku University Tohoku Medical Megabank Organization)
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2020-05-01
Description

Research collaboration for early elucidation of hospital and pathology of congenital edentulism.

toregem.co.jp
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Portugal-based regenerative medicine and cell therapy CDMO with dental/cartilage applications. Comparable as an emerging regenerative medicine peer with similar pre-commercial stage and tissue regeneration focus.

2BioHorizons
TypeBroad incumbent
Description

Global dental implant and regenerative products company (Henry Schein subsidiary). Comparable as an established player in the dental regeneration space offering alternative solutions to natural tooth regrowth.

TypeBroad incumbent
Description

Swiss-listed global leader in dental implants and tooth replacement. Most relevant dental-industry incumbent that Toregem's tooth regeneration drug would disrupt long-term.

4Dentsply Sirona
TypeBroad incumbent
Description

Largest global manufacturer of dental equipment, technologies, and consumables. Broad incumbent in dental solutions whose existing implant and prosthetic offerings are the incumbent alternative to Toregem's therapy.

TypeEmerging player
Description

Australia-listed clinical-stage regenerative medicine company developing cellular therapies. Comparable as a peer regenerative-medicine developer pursuing novel mechanism-driven therapies with similar regulatory and commercialization risk profile.

6Pluristem Therapeutics
TypeEmerging player
Description

Israel-based clinical-stage cell therapy company in regenerative medicine. Comparable as a small-cap clinical regenerative medicine company facing similar Phase II/III execution risk and capital-raising dynamics.

7AnGes MG
TypeRegional player
Description

Japan-listed clinical-stage biopharmaceutical company developing gene and regenerative therapies. Comparable as a Japan-domiciled clinical-stage biotech with similar regulatory pathway (PMDA), capital structure, and commercialization dynamics.

8Takara Bio
TypeRegional player
Description

Japan-listed biotechnology company with cell and gene therapy capabilities. Comparable as a Japanese biotech peer operating in regenerative medicine, sharing the PMDA regulatory pathway and Japanese investor ecosystem.

TypeBroad incumbent
Description

Japan-listed global pharmaceutical company with deep regenerative medicine presence (acquired Ocata). Already an investor in Toregem via Astellas Venture Management and a likely strategic acquirer of clinical-stage regenerative assets.

TypeEmerging player
Description

US-based clinical-stage biotech developing peptide-based bone and dental regeneration therapeutics (i-FACTOR). Comparable as a small clinical-stage company commercializing novel biologic mechanisms for dental/oral tissue regeneration.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Toregem BioPharma

Regenerative Biopharmaceuticalstoregem.co.jp

Toregem BioPharma is a Kyoto University spin-off developing TRG035, a humanized anti-USAG-1 antibody designed to regenerate natural teeth in patients with congenital edentulism. The clinical-stage biotech is preparing Phase II trials in Japan and US clinical entry, targeting rare genetic tooth agenesis first.

What Toregem BioPharma does

Toregem BioPharma Co., Ltd. is a privately held, Kyoto University spin-off biopharmaceutical company founded in May 2020 to develop the world's first therapeutic that regenerates natural human teeth. The company's lead and only clinical asset is TRG035, a humanized monoclonal antibody that neutralizes USAG-1 (Uterine Sensitization-Associated Gene-1), a protein that normally inhibits tooth bud development; by blocking USAG-1, TRG035 is intended to reactivate dormant tooth buds and induce the growth of new natural teeth. The technology originated from over two decades of basic research by co-founder and CTO Dr. Katsu Takahashi at Kyoto University Graduate School of Medicine, with proof-of-concept demonstrated in animal models (mice, ferrets, dogs) and published in Science Advances in 2021.

The company's initial therapeutic focus is severe congenital partial anodontia (先天性無歯症), a rare genetic condition where patients lack permanent tooth buds. TRG035 received Japan MHLW Orphan Drug designation in September 2025, completed domestic Phase I clinical trials without serious adverse events, and is now preparing for Phase II trials in Japan while concurrently advancing US clinical development following a successful US FDA Pre-IND meeting in November 2025. The stated longer-term ambition is to expand the same mechanism into acquired tooth loss (cavities, periodontal disease, trauma) and elderly oral frailty, addressing a potential Japanese patient population of approximately 3 million.

Toregem generates no commercial revenue; the company is funded entirely by equity financing and government/non-dilutive grants. Cumulative funding including subsidies reached approximately JPY 4.6 billion (USD 29 million) as of May 2026, with a Pre-Series C round of JPY 850 million (USD 5.3 million) led by JIC Venture Growth Investments. The company employs 13 people as of April 2026 and operates from Kyoto, Japan. The GTM motion is sales-led to medical institutions via investigator-initiated clinical trials, with future commercial distribution planned through standard pharmaceutical channels upon regulatory approval.

Toregem BioPharma firmographics

Firmographics
Name
Toregem BioPharma
Legal name
トレジェムバイオファーマ株式会社
Website
https://toregem.co.jp
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Toregem BioPharma is a Kyoto University spin-off developing TRG035, a humanized anti-USAG-1 antibody designed to regenerate natural teeth in patients with congenital edentulism. The clinical-stage biotech is preparing Phase II trials in Japan and US clinical entry, targeting rare genetic tooth agenesis first.
Ownership category
akta.pro rank

Toregem BioPharma industry classification

Industry
Product category
Regenerative Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Offices of Dentists (62121), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLABACAI
Periodontal Regeneration (GTR/EMD/Biologics)
Healthcare & Life Sciences/Dental Care Services/Periodontics (Gum & Implant Services)
SECONDARYHLABAAAA
Preventive & Routine General Dentistry (Exams/Cleanings/Sealants/Fluoride)

Keywords

  • Tooth regeneration therapeutics
  • Anti-USAG-1 antibody
  • Regenerative biopharmaceuticals
  • Congenital edentulism treatment
  • Clinical stage biotechnology

Where Toregem BioPharma is headquartered

Location

Headquarters

HQ city
Kyoto
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

Toregem BioPharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Tooth Regeneration Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing a novel tooth regeneration treatment (TRG035). Revenue will be generated through product sales upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Toregem BioPharma product offering

Product offering

Core offering

Toregem BioPharma is developing TRG035, a humanized anti-USAG-1 neutralizing monoclonal antibody that suppresses the USAG-1 protein, which normally inhibits tooth bud growth, thereby enabling patients' own dormant tooth buds to develop into natural teeth. The lead indication is congenital edentulism (congenital tooth agenesis), with future expansion planned to acquired tooth loss and oral frailty in the elderly; the product is currently advancing through Phase II clinical trials in Japan and pre-IND regulatory engagement with the US FDA.

Product overview

Toregem BioPharma is developing a single core product: TRG035, a humanized anti-USAG-1 antibody drug for tooth regeneration. The company is pursuing clinical development of this first-in-class regenerative antibody therapeutic, initially targeting congenital edentulism (congenital tooth agenesis), with plans to eventually expand to acquired tooth loss and oral frailty in the elderly. The product works by suppressing the USAG-1 protein that inhibits tooth bud growth, allowing new natural teeth to develop.

Differentiator

Problem solved

Functional benefit

Products and services

  • TRG035 (Anti-USAG-1 Antibody) A humanized anti-USAG-1 neutralizing monoclonal antibody drug designed to suppress the USAG-1 protein that inhibits tooth bud growth, enabling patients' own dormant tooth buds to develop into natural teeth. Intended for congenital edentulism (initial indication) and planned expansion to acquired tooth loss; administered as a single injection. Currently in Phase II clinical development in Japan with parallel US FDA Pre-IND engagement.

Quantifiable outcome

  • Phase I clinical trials at Kyoto University Hospital completed without serious adverse events
  • +2 more outcomes

Companies that use Toregem BioPharma

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Toregem BioPharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Toregem BioPharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • 京都大学 (Kyoto University)coreStrategic or Co-development Partner · 1 May 2020Technology origin - company founded based on research from Kyoto University Graduate School of Medicine, Department of Oral and Maxillofacial Surgery led by Dr. Katsu Takahashi.
  • 公益ражение田附興風会医学研究所北野病院 (Kitano Hospital, Tazuke Kofukai Medical Research Institute)coreStrategic or Co-development Partner · 1 May 2020Clinical trial partner conducting investigator-initiated clinical trials for tooth regeneration treatment. Dr. Takahashi serves as Chief of Oral and Maxillofacial Surgery.
  • 東北大学東北リカール・メガバンク機構 (Tohoku University Tohoku Medical Megabank Organization)supportingStrategic or Co-development Partner · 1 May 2020Research collaboration for early elucidation of hospital and pathology of congenital edentulism.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Toregem BioPharma competitors and assessment

Company assessment

Emerging players

  • Stemmatters: Portugal-based regenerative medicine and cell therapy CDMO with dental/cartilage applications. Comparable as an emerging regenerative medicine peer with similar pre-commercial stage and tissue regeneration focus.
  • Mesoblast: Australia-listed clinical-stage regenerative medicine company developing cellular therapies. Comparable as a peer regenerative-medicine developer pursuing novel mechanism-driven therapies with similar regulatory and commercialization risk profile.
  • Pluristem Therapeutics: Israel-based clinical-stage cell therapy company in regenerative medicine. Comparable as a small-cap clinical regenerative medicine company facing similar Phase II/III execution risk and capital-raising dynamics.
  • Cerapedics: US-based clinical-stage biotech developing peptide-based bone and dental regeneration therapeutics (i-FACTOR). Comparable as a small clinical-stage company commercializing novel biologic mechanisms for dental/oral tissue regeneration.

Broad incumbents

  • BioHorizons: Global dental implant and regenerative products company (Henry Schein subsidiary). Comparable as an established player in the dental regeneration space offering alternative solutions to natural tooth regrowth.
  • Straumann Group: Swiss-listed global leader in dental implants and tooth replacement. Most relevant dental-industry incumbent that Toregem's tooth regeneration drug would disrupt long-term.
  • Dentsply Sirona: Largest global manufacturer of dental equipment, technologies, and consumables. Broad incumbent in dental solutions whose existing implant and prosthetic offerings are the incumbent alternative to Toregem's therapy.
  • Astellas Pharma: Japan-listed global pharmaceutical company with deep regenerative medicine presence (acquired Ocata). Already an investor in Toregem via Astellas Venture Management and a likely strategic acquirer of clinical-stage regenerative assets.

Regional players

  • AnGes MG: Japan-listed clinical-stage biopharmaceutical company developing gene and regenerative therapies. Comparable as a Japan-domiciled clinical-stage biotech with similar regulatory pathway (PMDA), capital structure, and commercialization dynamics.
  • Takara Bio: Japan-listed biotechnology company with cell and gene therapy capabilities. Comparable as a Japanese biotech peer operating in regenerative medicine, sharing the PMDA regulatory pathway and Japanese investor ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights8 records

Customer concentration

Toregem BioPharma social profiles

Digital presence

Toregem BioPharma compliance and trust

Trust signal

Compliance1 record

Toregem BioPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Toregem BioPharma leadership team

Management profile

Number of profiles

Profiles7 records

Toregem BioPharma funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Toregem BioPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Toregem BioPharma

What does Toregem BioPharma do?

Toregem BioPharma is developing TRG035, a humanized anti-USAG-1 neutralizing monoclonal antibody that suppresses the USAG-1 protein, which normally inhibits tooth bud growth, thereby enabling patients' own dormant tooth buds to develop into natural teeth. The lead indication is congenital edentulism (congenital tooth agenesis), with future expansion planned to acquired tooth loss and oral frailty in the elderly; the product is currently advancing through Phase II clinical trials in Japan and pre-IND regulatory engagement with the US FDA.

Is Toregem BioPharma a public or private company?

Toregem BioPharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Toregem BioPharma founded?

Toregem BioPharma was founded in 2020. It employs 1 to 10 people.

Where is Toregem BioPharma based?

Toregem BioPharma is headquartered in Kyoto, Japan, in the Asia region.

How does Toregem BioPharma make money?

One revenue line is on record: tooth Regeneration Drug Development and Commercialization.

Who are Toregem BioPharma's main competitors?

Emerging players on record are Stemmatters, Mesoblast, Pluristem Therapeutics and Cerapedics. Broad incumbents are BioHorizons, Straumann Group, Dentsply Sirona and Astellas Pharma. Regional players are AnGes MG and Takara Bio.

Does Toregem BioPharma have an API?

No public API is recorded for Toregem BioPharma.

What industry is Toregem BioPharma in?

Toregem BioPharma's product category is Regenerative Biopharmaceuticals. Its primary akta.pro industry code is HLABACAI, Periodontal Regeneration (GTR/EMD/Biologics), with a secondary code of HLABAAAA, Preventive & Routine General Dentistry (Exams/Cleanings/Sealants/Fluoride). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DentistryTooth regrowth in adults: what we know so farMultiple research approaches for regenerating teeth are under development, including antibody therapy, stem cell regeneration, bioengineering, and mineral enamel repair, though no publicly available tooth regrowth treatment currently exists. Toregem BioPharma raised approximately US$5.3 million in May 2026 to support Phase II clinical trials of its experimental antibody treatment TRG035 in Japan, following successful Phase I safety trials at Kyoto University Hospital that concluded without serious adverse events. Researchers aim to have the treatment ready for general use by 2030, though this target remains provisional pending further efficacy data and regulatory approval.FuturismPlans Accelerated for Human Trials of Tooth RegenerationJapanese pharmaceutical company Toregem Biopharma has raised approximately $5.3 million in its latest financing round to accelerate clinical development of a tooth regeneration treatment, including plans for Phase 2 human trials in Japan. The treatment uses a neutralizing antibody to suppress the USAG-1 protein that inhibits tooth growth, with the company having demonstrated success in restoring teeth in mice in a 2021 study and arguing the approach could work in humans in a 2024 study.The Times of IndiaJapanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trials - The Economic TimesKyoto-based Toregem BioPharma has raised approximately $5.3 million (¥850 million) in a Pre-Series C financing round to advance its experimental tooth-regeneration drug TRG035 into Phase II clinical trials, bringing the company's total cumulative funding to over $29 million. The drug works by blocking a protein called USAG-1 that suppresses tooth growth, with the aim of stimulating dormant tooth buds to enable natural tooth regeneration. The initial target population is children with congenital tooth agenesis, though the company sees potential future applications for tooth loss due to aging, decay, or injury.The Times of IndiaJapanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trialsToregem BioPharma raised $5.3 million in a Pre-Series C round to advance Phase II trials of its tooth-regeneration drug TRG035. The drug blocks USAG-1 to activate dormant tooth buds, targeting congenital tooth agenesis. The company plans future U.S. trials, though experts caution results remain preliminary.ToregemToregem Raises Approximately USD 5.3 Million (JPY 850 Million) in Pre-Series C Financing;Total Past Funding Exceeds USD 29 Million (JPY 4.6 Billion)With this fundinig, we will accelerate the clinicalToregem raised approximately $5.3 million in pre-Series C financing, bringing cumulative equity funding to about $2.6 billion and total funding to over $29 million. The company will use the funds to conduct Phase II trials of TRG035 in Japan and prepare for U.S. development.The Times of IndiaForget implants! New drug can regrow human teeth naturally, Kiran Mazumdar-Shaw shares a video of how medicine works - The Economic TimesJapanese biotech firm Toregem Biopharma has developed a drug that targets the USAG-1 protein to stimulate natural tooth regrowth, successfully tested on mice and now in human clinical trials at Kyoto University Hospital since October. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, shared the innovation on social media, calling it an "amazing discovery" that could make dental implants obsolete. Researchers aim to commercialize the drug primarily for children by 2030, with initial focus on patients born without six or more permanent teeth.Boing BoingBiotech startup developing drug to grow more teethToregem Biopharma, spun off from Kyoto University, is developing an antibody drug to stimulate new tooth growth from tooth buds. The drug inhibits a protein that suppresses tooth growth, and in 2018 it induced new teeth in ferrets. The company aims to bring the drug to market by 2030 for treating anodontia and replacing lost adult teeth.ABCJapanese company developing drug to grow new teeth, plans for clinical trials on humans in 2024Toregem Biopharma, a Japanese company, is developing an antibody drug that inactivates the USAG-1 protein to enable tooth growth. The company plans to begin human clinical trials in July 2024, with a market launch by 2030. It also intends a second trial on children born without teeth.The Japan TimesJapan pharma startup developing world-first drug to grow new teethToregem Biopharma, a Japanese startup, is developing a drug to stimulate new tooth growth, with clinical trials in healthy adults planned for July 2024. The team previously grew new teeth in mice and ferrets, and a 2025 trial for children with anodontia is expected. The drug may also be used for adults who lost teeth due to cavities.